Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946]

Leuk Res. 2024 Jan:136:107430. doi: 10.1016/j.leukres.2023.107430. Epub 2024 Jan 9.

Authors

Andrew J Klink¹, Ajeet Gajra¹, Russell L Knoth², Landon Marshall¹, Ying Hou¹, Ali McBride³, Ronda Copher²

Affiliations

¹ Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA.
² Brystol Meyers Squibb, 86 Morris Avenue, Summit, NJ, USA.
³ Brystol Meyers Squibb, 86 Morris Avenue, Summit, NJ, USA. Electronic address: Ali.McBride@bms.com.

PMID: 38199929
DOI: 10.1016/j.leukres.2023.107430

No abstract available

Publication types

Published Erratum